Company News: Page (1) of 1 - 09/08/17 Email this story to a friend. email article Print this page (Article printing at page facebook

Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress

- 41% confirmed ORR for patients on combination of binimetinib, encorafenib and cetuximab -- Median duration of treatment was 5.6 months at time of analysis and 76% of patients remain on study treatme... (September 08, 2017)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Pro AV,Management,Presentors,Prosumer/Consumer,Business,Marketing,Standards/Initiatives,Business Issues,Internet Media,Presentation,Channel/Distribution,Marketing,Corporate/Company,Events, webcast,USA,Israel, Inc.,AES Attendees,Medicine,Disease,healthcare,Cancer,Surgery,Medication,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved